Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. (Q46682024)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 March 2008

Language	Label	Description	Also known as
English	Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.	scientific article published on 4 March 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

0 references

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Claire F. Verschraegen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Alonso V Pacheco

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Kanwaldeep Rasila

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Sang-Joon Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Ian Rabinowitz

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Laurence Elias

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Fa Chyi Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

4 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

610-615

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Rising incidence of renal cell cancer in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Immunotherapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

13-cis-Retinoic Acid Plus Interferon -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Cancer immunotherapy: the interferon-alpha experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Application of IL-2 and other cytokines in renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Application of retinoids in the treatment of renal cell carcinoma--a futile effort?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

The treatment of advanced renal cell cancer with high-dose oral thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Functions of the von Hippel-Lindau tumour suppressor protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.09.001

7 January 2021

Identifiers

10.1016/J.UROLONC.2007.09.001

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18367103%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46682024&oldid=1518774949"